NVCR News and Press, NovoCure Limited From 11/08/22

Some investors prefer boring stocks. That's completely understandable. Boring stocks often deliver the best long-term returns. They're like the tortoise in Aesop's classic fable about the hare and the tortoise. But other investors seek more excitement. They know that hares win plenty of...

At the heart of the medical device space isn’t just new technologies for diagnostics but also substitutes for potentially addictive and life-destroying drugs. Anything you can do with physical-external stimuli instead of pills that impact the brain is possibly a life-changing option fo...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...

Summary A bear market is a highly opportunistic time for you to average down on fundamentally robust companies. NovoCure is a phenomenal growth stock that recently transitioned into a stalwart. Though NovoCure posted stellar growth in the previous few years, there are still su...

Little Orphan Annie had it right: The sun will come out tomorrow. Although we're in a bear market now, stocks will rebound in time. We asked three Motley Fool contributors which stocks they're especially optimistic about. Here's why they think that Ginkgo Bioworks Holdings (NYSE: ...

Image source: The Motley Fool. Novocure (NASDAQ: NVCR) Q3 2022 Earnings Call Oct 27, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Novocure (NVCR) Q3 2022 Earnings Call Transcript

NovoCure Limited (NVCR) Q3 2022 Earnings Conference Call October 27, 2022 08:00 ET Company Participants Ingrid Goldberg - Vice President of Investor Relations William Doyle - Executive Chairman Asaf Danziger - President & Chief Executive Officer Ashley Co...

NovoCure press release ( NASDAQ: NVCR ): Q3 GAAP EPS of -$0.25 beats by $0.03 . Revenue of $130.99M (-2.0% Y/Y) misses by $2.39M . The United States, EMEA and Japan contributed $102.7 million, $14.3 million, and $7.9 million in quarterly net revenues,...

Quarterly net revenues of $131 million with $52 million invested in research & development initiatives Entering a transformational period with multiple pivotal trial readouts anticipated in coming quarters Novocure (NASDAQ: NVCR) today reported financial results ...

NovoCure Limited ( NASDAQ: NVCR ), the developer of tumor treating fields (TTFields) devices to treat cancer, reached a four-month low intraday on Monday after Piper Sandler downgraded the company despite positive views on a Phase 3 readout expected in Q1 2023. NVCR advances...